Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yim, Sun Young | - |
dc.contributor.author | Chun, Ho Soo | - |
dc.contributor.author | Lee, Jae Seung | - |
dc.contributor.author | Lim, Ji-Hwan | - |
dc.contributor.author | Kim, Tae Hyung | - |
dc.contributor.author | Kim, Beom Kyung | - |
dc.contributor.author | Kim, Seung Up | - |
dc.contributor.author | Park, Jun Yong | - |
dc.contributor.author | Ahn, Sang Hoon | - |
dc.contributor.author | Kim, Gyoung Min | - |
dc.contributor.author | Won, Jong Yun | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Kim, Yun Hwan | - |
dc.contributor.author | Um, Soon Ho | - |
dc.contributor.author | Kim, Do Young | - |
dc.date.accessioned | 2022-02-25T01:49:31Z | - |
dc.date.available | 2022-02-25T01:49:31Z | - |
dc.date.issued | 2022-01 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/55236 | - |
dc.description.abstract | Transarterial radioembolization (TARE) has become widely used in the treatment of HCC, one of the most common causes of cancer mortality worldwide. Here we investigated the long-term clinical outcomes of patients with hepatocellular carcinoma (HCC) treated with TARE in a multimedical center in Korea. A total of 149 patients treated with TARE from 2008–2014 were recruited. The pre-treatment HCC stage was classified according to the BCLC stage, of which C and D were defined as advanced HCC. Advanced HCC stage and Child–Turcotte–Pugh (CTP) score A were identified in 62 (42%) and 134 (90%) patients, respectively. Portal vein thrombosis (PVT) was identified in 58 patients (38.9%). The median time to progression (TTP) was 14 months, and the median overall survival (OS) and progression-free survival (PFS) were 18.6 and 8.9 months, respectively. The overall tumor response was 47%, and the disease control rate was 78%. OS and PFS differed significantly according to the presence of liver cirrhosis, extrahepatic metastasis, tumor response and curative treatment after TARE (all, p < 0.05). Multiple tumors and major PVT were other independent factors related to OS, while the des-gamma carboxy protein level predicted PFS (all, p < 0.05). Tumor size was an independent predictor of tumor response. TTP, OS and PFS all differed among BCLC stages.The serious adverse effect after TARE was clinically not significant. Therefore, TARE is safe and effective in treating early to advanced HCCs. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | - |
dc.title | Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/cancers14020385 | - |
dc.identifier.scopusid | 2-s2.0-85122857831 | - |
dc.identifier.wosid | 000747626100001 | - |
dc.identifier.bibliographicCitation | Cancers, v.14, no.2 | - |
dc.citation.title | Cancers | - |
dc.citation.volume | 14 | - |
dc.citation.number | 2 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | INTERNAL RADIATION-THERAPY | - |
dc.subject.keywordPlus | CONCURRENT CHEMORADIATION THERAPY | - |
dc.subject.keywordPlus | DOXORUBICIN-ELUTING BEADS | - |
dc.subject.keywordPlus | Y-90 RESIN MICROSPHERES | - |
dc.subject.keywordPlus | CHEMOEMBOLIZATION | - |
dc.subject.keywordPlus | SORAFENIB | - |
dc.subject.keywordPlus | LONG | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
dc.subject.keywordAuthor | hepatocellular carcinoma | - |
dc.subject.keywordAuthor | overall survival | - |
dc.subject.keywordAuthor | progression-free survival | - |
dc.subject.keywordAuthor | risk factor | - |
dc.subject.keywordAuthor | transarterial chemoembolization | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.